Immunogenicity and Safety of GSK Biologicals' Thimerosal-Free TIV Flu Vaccine Versus a Licensed Comparator in Children.
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 19 Feb 2018 Results of pooled post hoc analysis of NCT00764790, NCT00980005 and NCT00383123 trials assessing the relation of fever and antipyretic use to each other and to vaccine immunogenicity published in the Pediatric Infectious Disease Journal
- 17 Jun 2009 Actual patient number (3318) added as reported by ClinicalTrials.gov.
- 17 Jun 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.